Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Average Rating of “Moderate Buy” by Analysts

Achieve Life Sciences, Inc. (NASDAQ:ACHV) has earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $15.50.

A number of equities research analysts have recently weighed in on ACHV shares. Weiss Ratings restated a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Monday. Citizens Jmp began coverage on shares of Achieve Life Sciences in a research report on Tuesday, November 25th. They issued a “market outperform” rating and a $19.00 target price on the stock. Raymond James Financial restated a “strong-buy” rating on shares of Achieve Life Sciences in a research report on Monday, November 24th. Finally, Citigroup began coverage on Achieve Life Sciences in a research note on Tuesday, November 25th. They set an “outperform” rating on the stock.

Achieve Life Sciences Trading Down 0.5%

Shares of ACHV stock opened at $4.32 on Friday. The company has a market capitalization of $229.95 million, a PE ratio of -3.13 and a beta of 1.69. Achieve Life Sciences has a 52-week low of $1.84 and a 52-week high of $5.78. The business’s fifty day moving average is $4.53 and its 200 day moving average is $3.48. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.14 and a current ratio of 5.14.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). On average, equities research analysts anticipate that Achieve Life Sciences will post -1.17 EPS for the current fiscal year.

Institutional Trading of Achieve Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences in the first quarter worth approximately $32,000. Next Capital Management LLC purchased a new stake in Achieve Life Sciences during the 3rd quarter valued at $51,000. OneDigital Investment Advisors LLC purchased a new stake in Achieve Life Sciences during the 3rd quarter valued at $63,000. Sender Co & Partners Inc. bought a new stake in Achieve Life Sciences in the 2nd quarter worth $56,000. Finally, Bank of America Corp DE increased its position in shares of Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 9,617 shares during the period. Institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.